2nd Quarter - Report

GENENTECH, INC for GENENTECH INC

Firm
Client
Income
—
Expenses
$910,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

8 issue areas, each in the filer's own words, with who lobbied on it and where.

Trade (domestic/foreign) TRD

Issues relating to U.S. trade policy and TransPacific Partnership.

LobbyistCovered position, as disclosed
DAVID B BURT —
ANNA GRIFFIN —

Contacted: Food & Drug Administration (FDA); SENATE; Centers For Disease Control & Prevention (CDC); Health & Human Services, Dept of (HHS); U.S. Trade Representative (USTR); Executive Office of the President (EOP); HOUSE OF REPRESENTATIVES

Taxation/Internal Revenue Code TAX

Issues related to several tax issues and tax reform. Issues relating to corporate tax reform including taxation of foreign-owned US corporations. Issues relating to proposed regulations under Section 385 of the Internal Revenue Code.

LobbyistCovered position, as disclosed
DAVID B BURT —
ANNA GRIFFIN —

Contacted: Executive Office of the President (EOP); U.S. Trade Representative (USTR); SENATE; Health & Human Services, Dept of (HHS); Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; Centers For Disease Control & Prevention (CDC)

Copyright/Patent/Trademark CPT

Intellectual Property and Process Patent Issues. General IP Issues; Patent Litigation Reform; Transpacific Partnership Agreement.

LobbyistCovered position, as disclosed
DAVID B BURT —
ANNA GRIFFIN —
KATHERINE RAAB —
ANDREW WESLEY WOMACK New —

Contacted: Centers For Disease Control & Prevention (CDC); Executive Office of the President (EOP); HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); SENATE; U.S. Trade Representative (USTR); Health & Human Services, Dept of (HHS)

Health Issues HCR

H.R. 6 21st Century Cures Act. Innovation for Healthier Americans -- Senate HELP Committee. Implementation issues related to Pharmaceutical Quality Quality, Security & Sccoubtability Act (PL 113-54). Issues related to the 340B Drug Discount Program. Drug pricing issues. White House Cancer Moonshot & Precision Medicine initiatives. Part B Drug payment issues, CMMI Part B Payment model. Issues related to the implementation of the follow-on biologies provisions in P.L. 11-1148 "PPACA".

LobbyistCovered position, as disclosed
DAVID B BURT —
ANNA GRIFFIN —
KATHERINE RAAB —
ANDREW WESLEY WOMACK New —

Contacted: Centers For Disease Control & Prevention (CDC); Food & Drug Administration (FDA); U.S. Trade Representative (USTR); Executive Office of the President (EOP); Health & Human Services, Dept of (HHS); SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 6 (114th)

Medicare/Medicaid MMM

Issues relating to CMMI proposed CMMI Part B demo (81 FR 13229) 340B drug discount program. 21st Century Cures initiative. Implementation of Medicare Pharmaceutical coverage and reimbursement. Follow-on biologies and Medicare Physician Fee schedule rule to blend ASP for biosimilars.

LobbyistCovered position, as disclosed
DAVID B BURT —
ANNA GRIFFIN —
KATHERINE RAAB —
ANDREW WESLEY WOMACK New —

Contacted: Executive Office of the President (EOP); SENATE; HOUSE OF REPRESENTATIVES; U.S. Trade Representative (USTR); Centers For Disease Control & Prevention (CDC); Health & Human Services, Dept of (HHS); Food & Drug Administration (FDA)

Budget/Appropriations BUD

S.3040, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2017. H.R.5054/S.2956, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2017. Appropriations for Biosecurity Preparedness; HCR/CDC/HHS - Replenishment of Influenza Antiviral Stockpile.

LobbyistCovered position, as disclosed
DAVID B BURT —
ANNA GRIFFIN —
KATHERINE RAAB —
ANDREW WESLEY WOMACK New —

Contacted: SENATE; U.S. Trade Representative (USTR); HOUSE OF REPRESENTATIVES; Centers For Disease Control & Prevention (CDC); Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS); Executive Office of the President (EOP)

Bills named: S. 2956 (114th), H.R. 5054 (114th), S. 3040 (114th)

Pharmacy PHA

Implementation of the Pharmaceutical, Quality, Safety & Accountability Act (P.L. 113-54). 340B drug discount program.

LobbyistCovered position, as disclosed
DAVID B BURT —
ANNA GRIFFIN —
KATHERINE RAAB —
ANDREW WESLEY WOMACK New —

Contacted: Centers For Disease Control & Prevention (CDC); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Executive Office of the President (EOP); Food & Drug Administration (FDA); U.S. Trade Representative (USTR); SENATE

Homeland Security HOM

S.456, Cyber Threat Sharing Act of 2015, S.177/H.R.1770, Data Security and Breach Notification Act of 2015, S.1027, Data Breach Notification and Punishing Cyber Criminals Act of 2015, S.961/H.R.2205, Data Security Act of 2015; data security and cybersecurity issues.

LobbyistCovered position, as disclosed
ANNA GRIFFIN —
KATHERINE RAAB —

Contacted: Executive Office of the President (EOP); U.S. Trade Representative (USTR); Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; SENATE; Centers For Disease Control & Prevention (CDC); Health & Human Services, Dept of (HHS)

Bills named: S. 1027 (114th), S. 177 (114th), S. 961 (114th), S. 456 (114th), H.R. 1770 (114th), H.R. 2205 (114th)

Foreign entities

Foreign owners and affiliates the filer disclosed. Amounts are as declared on this filing.

EntityCountryPrincipal place of businessOwnershipContribution declared
ROCHE HOLDING LTD Switzerland Switzerland 100.0% —

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.